VRTX - バ―テックス・ファ―マシュ―ティカルズ （Vertex Pharmaceuticals Incorporated） バ―テックス・ファ―マシュ―ティカルズVRTXのチャート
VRTXの企業情報
| symbol | VRTx |
|---|---|
| 会社名 | Vertex Pharmaceuticals Inc. （バ―テックス・ファ―マシュ―ティカルズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 バーテックス・ファーマシューティカルズ（Vertex Pharmaceuticals Incorporated）は重篤な疾患の治療薬の発見・開発・生産・商品化に従事する会社である。同社は嚢胞性線維症（CF）の治療法の開発と商品化に注力し、他の適応症における研究開発プログラムの推進に取り組んでいる。同社の販売されている医薬品は、ORKAMBIおよびKALYDECOである。ORKAMBI（ivacaftorと組み合わせたlumacaftor）は、その嚢胞性線維症膜貫通コンダクタンス調節因子（CFTR）遺伝子にDelta-F508（F508del）突然変異を2コピー（同型接合）有する患者の治療薬として承認される。KALYDECO（ivacaftor）は、CFTR遺伝子にG551D突然変異または他の特定の突然変異を有するCF患者の治療のために承認されている。CF分野の開発プログラムには、Tezacaftor（VX-661）、VX-152、VX-440、VX-659、VX-445、VX-371などがあります。VX-152、VX-440、VX-659、VX-445はCFTR補正剤である。 バ―テックス・ファ―マシュ―ティカルズは米国のバイオ医薬品企業。低分子薬品の発見、開発、製造、商業化に従事する。主要医薬品にはC型肝炎ウイルス治療薬「INCIVEK」と、嚢胞性線維症治療薬「KALYDECO」の2種類がある。その他、自己免疫疾患やインフルエンザ治療用の医薬品の開発にも従事。本社はボストン。 Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus. |
| 本社所在地 | 50 Northern Avenue Boston MA 02210 USA |
| 代表者氏名 | Jeffrey M. Leiden ジェフリー・M・ライデン |
| 代表者役職名 | Chairman of the Board President Chief Executive Officer 取締役会長兼最高経営責任者（CEO） |
| 電話番号 | +1 617-341-6393 |
| 設立年月日 | 32509 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 1991年 |
| 従業員数 | 2300人 |
| url | www.vrtx.com |
| nasdaq_url | https://www.nasdaq.com/symbol/vrtx |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） 423.58200 |
| 終値（lastsale） | 185.37 |
| 時価総額（marketcap） | 47373145892.43 |
| 時価総額 | 時価総額（百万ドル） 44899.32 |
| 売上高 | 売上高（百万ドル） 2622.755 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 42724.3 |
| 当期純利益 | 当期純利益（百万ドル） 415.10300 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Vertex Pharmaceuticals Incorporated revenues increased 11% to $1.39B. Net income applicable to common stockholders increased 57% to $417.5M. Revenues reflect Product revenues net increase of 40% to $1.39B. Net income benefited from Other income (expense) net increase from $3.1M (expense) to $150.7M (income) Restructuring expenses (income) decrease from $13.5M (expense) to $14K (income). |
VRTXのテクニカル分析
VRTXのニュース
Vertex Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors 2023/02/02 22:30:00 MarketWatch
Shares of Vertex Pharmaceuticals Inc. slid 4.25% to $303.78 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the…
Top 5 4th Quarter Trades of FOSTER DYKEMA CABOT & CO INC/MA 2023/02/01 20:00:08 GuruFocus
Related Stocks: IEFA , SHW , LLY , VRTX , XLV ,
MOODY LYNN & LIEBERSON, LLC Buys 4, Sells 1 in 4th Quarter 2023/02/01 20:00:07 GuruFocus
Related Stocks: GOOGL , 48D , UBER , VRTX , NEE ,
$100 Invested In This Stock 15 Years Ago Would Be Worth $1,600 Today 2023/01/31 21:04:32 Benzinga
Vertex Pharmaceuticals (NASDAQ: VRTX ) has outperformed the market over the past 15 years by 12.93% on an annualized basis producing an average annual return of 20.63%. Currently, Vertex Pharmaceuticals has a market capitalization of $82.90 billion. Buying $100 In VRTX: If … Full story available on Benzinga.com
This Clue Helps Spot The Best Stocks To Watch, Including These 11 2023/01/31 20:16:07 Investor''s Business Daily
The best stocks to watch often hail from the top-ranked industries. Here''s a look 11 stocks, including VRTX ad ULTA, that fit that bill.
Vertex to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 9 2023/01/04 13:00:00 Business Wire
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET/8:15 a.m. PT. A live webcast of management''s remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company''s website. About Vertex Vertex is a globa
Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab 2023/01/01 19:00:00 Seeking Alpha
Seeking Alpha contributors accurately predicted the 2022 bull run of AbbVie (ABBV), Vertex Pharma (VRTX), and Genmab (GMAB), sometimes even against the consensus. Read the full story here.
5 Stocks That Outperformed the S&P 500 in 2022 2022/12/30 20:06:22 GuruFocus
Stocks that outperformed as market finishes one of the worst years since 2008 Check out Vanguard Health Care Fund Stock Picks » Download GuruFolio Report of Vanguard Health Care Fund (Updated on 12/29/2022) , Check out Jim Simons Stock Picks » Download GuruFolio Report of Jim Simons (Updated on 12/29/2022) Related Stocks: VRTX , APD , FISV , MPC , VMW ,
Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues 2022/12/28 12:55:47 Seeking Alpha
Vertex Pharmaceuticals is doing very well with respect to sales of its CF franchise. Click here to read why VRTX is a great speculative biotech play.
Is Vertex Pharmaceuticals a Buy? 2022/12/27 11:15:00 The Motley Fool
There''s more growth ahead for this biotech giant.
Cashing out in biotech in 2022: On-target predictions for AbbVie, Vertex and Genmab 2023/01/01 19:00:00 Seeking Alpha
Seeking Alpha contributors accurately predicted the 2022 bull run of AbbVie (ABBV), Vertex Pharma (VRTX), and Genmab (GMAB), sometimes even against the consensus. Read the full story here.
5 Stocks That Outperformed the S&P 500 in 2022 2022/12/30 20:06:22 GuruFocus
Stocks that outperformed as market finishes one of the worst years since 2008 Check out Vanguard Health Care Fund Stock Picks » Download GuruFolio Report of Vanguard Health Care Fund (Updated on 12/29/2022) , Check out Jim Simons Stock Picks » Download GuruFolio Report of Jim Simons (Updated on 12/29/2022) Related Stocks: VRTX , APD , FISV , MPC , VMW ,
Vertex: Progress Towards Expanding Cystic Fibrosis Market Continues 2022/12/28 12:55:47 Seeking Alpha
Vertex Pharmaceuticals is doing very well with respect to sales of its CF franchise. Click here to read why VRTX is a great speculative biotech play.